Market Closed -
Other stock markets
|
After market 06:39:13 pm | |||
91.2 USD | -0.93% | 87.94 | -3.57% |
Apr. 24 | BioMarin Pharmaceutical Q1 Non-GAAP EPS, Revenue Increase -- Shares Down After Hours | MT |
Apr. 24 | (BMRN) BIOMARIN PHARMACEUTICAL Forecasts Fiscal Year 2024 EPS Range $2.75 - $2.95 | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-5.41% | 17.47B | |
-2.86% | 87.37B | |
+3.95% | 41.01B | |
-21.94% | 28.08B | |
+53.11% | 24.72B | |
-44.23% | 11.69B | |
-17.60% | 11.6B | |
-13.96% | 11.56B | |
-0.22% | 8.44B | |
+2.09% | 7.72B |
- Stock Market
- Equities
- BMRN Stock
- News BioMarin Pharmaceutical Inc.
- BioMarin Pharmaceutical Treatment for Duchenne Muscular Dystrophy Granted Orphan Drug Status by US FDA